Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Assessment of anti-adeno-associated virus (AAV) antibodies in patients prior to systemic gene therapy administration is an important consideration regarding efficacy and safety of the therapy. Approximately 30%-60% of individuals have pre-existing anti-AAV antibodies. Seroprevalence is impacted by multiple factors, including geography, age, capsid serotype, and assay type. Anti-AAV antibody assays typically measure (1) transduction inhibition by detecting the neutralizing capacity of antibodies and non-antibody neutralizing factors, or (2) total anti-capsid binding antibodies, regardless of neutralizing activity. Presently, there is a paucity of head-to-head data and standardized approaches associating assay results with clinical outcomes. In addition, establishing clinically relevant screening titer cutoffs is complex. Thus, meaningful comparisons across assays are nearly impossible. Although complex, establishing screening assays in routine clinical practice to identify patients with antibody levels that may impact favorable treatment outcomes is achievable for both transduction inhibition and total antibody assays. Formal regulatory approval of such assays as companion diagnostic tests will confirm their suitability for specific recombinant AAV gene therapies. This review covers current approaches to measure anti-AAV antibodies in patient plasma or serum, their potential impact on therapeutic safety and efficacy, and investigative strategies to mitigate the effects of pre-existing anti-AAV antibodies in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444 · cited 1×
“4,10,12 It is estimated that about 30% – 60% of the population have measurable antibodies to different AAV serotypes from a wild-type infection.”
BackgroundManno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 4×
“In humans, FIX expression was attenuated in a patient with pre-existing NAb titer of 1:17 who was administered an AAV2 vector to treat hemophilia B. 96 In another study, which evaluated rAAV (Spark100) GTx in hemophilia B patients, George et al. (2017) reported that the single participant with an…”
BackgroundInfluentialAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 1×
“…May be effective in the presence of low-titer (1:5 – 1:17) NAbs 93,96 (cid:1) The higher vector load could trigger an anti-capsid T cell response 96,136 , which is a potential safety risk, particularly in the setting of pre-existing humoral response Example: Tenfold increase in vector dose…”
BackgroundAdeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362 · cited 2×
“8 AAV sero-types differ in their tissue tropism 10,11 ; therefore, the selection of an appropriate AAV serotype further enables targeted tissue expression.”
BackgroundIgG placental transfer in healthy and pathological pregnancies
Palmeira, P., Quinello, C., Silveira-Lessa, A. L., Zago, C. A., & Carneiro-Sampaio, M. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/985646 · Cited by 1,037
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955 · cited 3×
“GTx-related approaches include using higher GTx doses, 72,116,117 co-administering empty “ decoy ” capsids, 72,97,115,116 local delivery to the target organ or tissue, 43,47,115,116,118 use of alternate capsids, or cloaking the rAAV capsid.”
BackgroundMethodOverview of complement activation and regulation
Noris, M., & Remuzzi, G. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2013.08.001 · Cited by 864
Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708538 · Cited by 762
Cited by
Salabarria, S. M., Corti, M., Coleman, K. E., Wichman, M. B., Berthy, J. A., D’Souza, P., Tifft, C. J., Herzog, R. W., Elder, M. E., Shoemaker, L. R., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci173510 · Cited by 159
“Complement activation by AAV is primarily antibody dependent (classical pathway), triggered by anti-capsid IgM and IgG antibodies that can cause complement-mediated cell damage (18).”
BackgroundInfluentialSelf-citationImmune Responses to Muscle-Directed Adeno-Associated Viral Gene Transfer in Clinical Studies
Kumar, S. R. P., Duan, D., & Herzog, R. W. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.056 · Cited by 28
B cell focused transient immune suppression protocol for efficient AAV readministration to the liver
Rana, J., Herzog, R. W., Muñoz-Melero, M., Yamada, K., Kumar, S. R. P., Lam, A. K., Markusic, D. M., Duan, D., Terhorst, C., Byrne, B. J., et al. (2024) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2024.101216 · Cited by 26
Self-citation
Metadata
- Authors
- Schulz, M., Levy, D. I., Petropoulos, C. J., Bashirians, G., Winburn, I., Mahn, M., Somanathan, S., Cheng, S. H., & Byrne, B. J.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2023-03
- Volume
- 31
- Issue
- 3
- Pages
- 616-630
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W4315643308
- Cited by
- 125
- References
- 55
- FWCI
- 18.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.